About UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1
UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 (B3GALNT1) is a protein
from Homo sapiens identified by UniProt accession
O75752, 331 residues long.
MolForge cross-references it against 0 known binders and
55 disease associations.
Target properties
| Protein name | UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 |
|---|
| UniProt accession | O75752 |
|---|
| Gene | B3GALNT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 331 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (55)
Diseases linked to this target (Open Targets).
- p phenotype · score 0.26
- self reported educational attainment · score 0.25
- chronotype measurement · score 0.21
- risky sexual behaviour measurement · score 0.12
- blood urea nitrogen measurement · score 0.09
- Hashimoto's thyroiditis · score 0.07
- hypothyroidism · score 0.06
- neoplasm · score 0.03
- non-small cell lung carcinoma · score 0.02
- lung adenocarcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75752-F1 | alphafold | PREDICTED | 90.50 | — |
Amino-acid sequence (331 residues)
MASALWTVLP SRMSLRSLKW SLLLLSLLSF FVMWYLSLPH YNVIERVNWM YFYEYEPIYR QDFHFTLREH SNCSHQNPFL VILVTSHPSD VKARQAIRVT WGEKKSWWGY EVLTFFLLGQ EAEKEDKMLA LSLEDEHLLY GDIIRQDFLD TYNNLTLKTI MAFRWVTEFC PNAKYVMKTD TDVFINTGNL VKYLLNLNHS EKFFTGYPLI DNYSYRGFYQ KTHISYQEYP FKVFPPYCSG LGYIMSRDLV PRIYEMMGHV KPIKFEDVYV GICLNLLKVN IHIPEDTNLF FLYRIHLDVC QLRRVIAAHG FSSKEIITFW QVMLRNTTCH Y
Explore UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets